Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 24: Blutdrucksenkung - Nephropathie Abb. 25: Niereninsuffizienz - Wirksamkeit Abb. 26: Telmisartan - Eigenschaften Aktuelles Bild - Abb. 27: Morgendliche Blutdrucksenkung Abb. 28: Klinische Wirksamkeit - MicardisPlus Abb. 29: Telmisartan - HCTZ Abb. 30: Telmisartan - HCTZ Zum letzten Bild
Abbildung 27: Morgendliche Blutdrucksenkung
This slide gives a summary of the benefits of telmisartan over active comparators in the early morning period. Except where indicated, all these studies used ABPM to measure the changes from baseline in the last 6 h of the dosing interval. Telmisartan was superior to losartan in a fixed-dose1 and a titration-to-response study.2 Telmisartan was superior to valsartan in two forced-titration studies.3,4 Telmisartan reduced DBP compared with amlodipine in the last 4 h of the dosing interval (assessed using ABPM).5 Telmisartan reduced trough blood pressure measured at home in the morning compared with perindopril.6 Two studies showed that telmisartan reduces early morning blood pressure compared with ramipril.7,8 1. Ding PY, et al. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004; 58: 16–22. 2. Smith DH, et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111–117. 3. White WB, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Impact on the early morning period. Am J Hypertens 2004; 17: 347–353. 4. Lacourcière Y, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203–210. 5. Lacourcière Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3: 295–302. 6. Ragot S, et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16: 865–873. 7. Williams B, et al. Superior blood pressure reduction in the last 6 h of the dosing interval with once-daily telmisartan versus ramipril. Hypertension 2004; 44: 576. 8. Lacourcière Y, et al. A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring. Hypertension 2004; 44: 576.
 
Morgendliche Blutdrucksenkung
Vorheriges Bild Nächstes Bild   


Abbildung 27: Morgendliche Blutdrucksenkung
This slide gives a summary of the benefits of telmisartan over active comparators in the early morning period. Except where indicated, all these studies used ABPM to measure the changes from baseline in the last 6 h of the dosing interval. Telmisartan was superior to losartan in a fixed-dose1 and a titration-to-response study.2 Telmisartan was superior to valsartan in two forced-titration studies.3,4 Telmisartan reduced DBP compared with amlodipine in the last 4 h of the dosing interval (assessed using ABPM).5 Telmisartan reduced trough blood pressure measured at home in the morning compared with perindopril.6 Two studies showed that telmisartan reduces early morning blood pressure compared with ramipril.7,8 1. Ding PY, et al. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004; 58: 16–22. 2. Smith DH, et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111–117. 3. White WB, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Impact on the early morning period. Am J Hypertens 2004; 17: 347–353. 4. Lacourcière Y, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203–210. 5. Lacourcière Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3: 295–302. 6. Ragot S, et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16: 865–873. 7. Williams B, et al. Superior blood pressure reduction in the last 6 h of the dosing interval with once-daily telmisartan versus ramipril. Hypertension 2004; 44: 576. 8. Lacourcière Y, et al. A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring. Hypertension 2004; 44: 576.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung